| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Carvone — Carvone is a chiral oxygenated monocyclic monoterpene ketone found mainly as enantiomeric forms in spearmint, caraway, dill, and related essential oils. It is best classified as a small-molecule natural product / volatile terpenoid flavor-fragrance compound, commonly abbreviated CRV. The biologically relevant forms are often reported as l-carvone, d-carvone, R-carvone, or S-carvone, but naming conventions are inconsistent across papers, so note the exact enantiomer stated by each source. Primary mechanisms (ranked):
Bioavailability / PK relevance: Carvone is lipophilic and volatile, with oral, dermal, and inhalational exposure relevance depending on formulation. Human PK/metabolism data exist for ingestion-correlated and topical/percutaneous exposure contexts, but anticancer studies generally use concentrations that are not directly matched to validated systemic anticancer exposure. Essential-oil delivery introduces variability from enantiomer ratio, co-terpenes, oxidation products, and formulation. In-vitro vs systemic exposure relevance: Common anticancer in-vitro effects occur at high micromolar to millimolar or microgram-per-millilitre ranges, and breast-cancer IC50 values around the millimolar range have been reported. These levels are likely above ordinary dietary flavor exposure and may exceed practical systemic exposure from food-like intake. Interpretation should therefore be concentration-constrained and formulation-dependent. Clinical evidence status: Preclinical for cancer. Evidence includes cancer cell-line studies, animal chemoprevention/tumor models, and mechanistic studies, but no credible cancer RCTs of carvone as a therapeutic agent were identified. Human studies involving carvone-containing preparations exist for non-cancer indications or mixtures, but they should not be treated as direct anticancer evidence for isolated carvone. Safety / regulatory status: Carvone is listed as a FEMA GRAS flavoring substance with CFR flavor-use reference, but this applies to intended flavor-use exposure, not therapeutic dosing. Major constraints include skin sensitization potential, enantiomer/formulation variability, volatile exposure, and uncertain safety at high supplemental or pharmacologic doses. Fragrance safety assessment data indicate no genotoxic concern under reviewed conditions, but l-carvone is considered a skin sensitizer. Carvone Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| The cytochrome P450 (CYP) family includes many isoenzymes that play key roles in metabolizing endogenous substances (like hormones) and xenobiotics (including drugs and toxins). Changes in the expression of these enzymes in various cancers can affect carcinogen activation, drug metabolism, and overall tumor biology, influencing both cancer risk and prognosis. CYP1B1 – Frequently overexpressed in several cancers including breast, ovarian, prostate, and colorectal cancers. – Its expression is often low in normal tissues, making it a potential target for selective cancer therapies. 2. CYP3A4 and CYP3A5 These enzymes are highly expressed in the liver, but their expression is also observed in extrahepatic tissues. – In cancer, CYP3A enzymes can be variably expressed; for instance, CYP3A4 may be upregulated in some liver cancers but downregulated in others. 3. CYP2E1 – CYP2E1 is expressed in the liver and extrahepatic tissues. – Elevated CYP2E1 activity can lead to increased production of reactive oxygen species (ROS), contributing to DNA damage and cancer progression. 4. CYP19A1 (Aromatase) – Aromatase converts androgens to estrogens and is expressed in adipose tissue as well as in certain tumors such as breast cancer. – Its local expression in breast tumors can increase estrogen levels, promoting hormone-dependent tumor growth. 5. CYP2C Family (e.g., CYP2C8, CYP2C9, CYP2C19) – These enzymes are involved in metabolizing various drugs and are expressed in the liver and intestines. – Their expression levels can be altered in different tumor types, potentially affecting drug metabolism. CYP450 enzymes are a large family with diverse roles in cancer biology. • Their expression in cancers (e.g., CYP1B1, CYP3A4/5, CYP2E1, CYP19A1) has been linked to both the development and progression of tumors, as well as influencing responses to therapy. |
| 6520- | CRV, | Health Benefits and Pharmacological Properties of Carvone |
| - | Review, | Nor, | NA |
| 6527- | CRV, | Preventive effect of D-carvone during DMBA induced mouse skin tumorigenesis by modulating xenobiotic metabolism and induction of apoptotic events |
| - | in-vivo, | Melanoma, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:411 Target#:1061 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid